Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Eric Fink Biography and Net Worth

Insider of Global Blood Therapeutics

Eric Fink serves as Chief Human Resource Officer of the Company. Prior to joining us, from 2010 until July 2019, he most recently served as Vice President, Human Resources, at Jazz Pharmaceuticals, a global biopharmaceutical company. While there, he held a variety of human resource senior leadership positions to develop human capital and organizational development strategies and scale the global HR operating model to better serve the expanding business. From 2008 to 2009, he held a leadership position in the sales training organization at Bayer Healthcare, a multinational pharmaceutical and life sciences company. From 1999 to 2008, he held various roles at GlaxoSmithKline, a global healthcare company, across a wide spectrum of the U.S. commercial function, including Sales, Sales Training, Commercial Analytics, and Sales Management. He received a B.S. in Biology from Pennsylvania State University and an M.S. in Organizational Leadership from Mercyhurst University.

What is Eric Fink's net worth?: The estimated net worth of Eric Fink is at least $353,476.89 as of May 10th, 2021. Mr. Fink owns 5,161 shares of Global Blood Therapeutics stock worth more than $353,477 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Fink may own. Learn More about Eric Fink's net worth.
How do I contact Eric Fink?: The corporate mailing address for Mr. Fink and other Global Blood Therapeutics executives is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Global Blood Therapeutics can also be reached via phone at (650) 741-7700 and via email at [email protected]. Learn More on Eric Fink's contact information.
Has Eric Fink been buying or selling shares of Global Blood Therapeutics?: Eric Fink has not been actively trading shares of Global Blood Therapeutics over the course of the past ninety days. Most recently, on Monday, May 10th, Eric Fink bought 500 shares of Global Blood Therapeutics stock. The stock was acquired at an average cost of $37.96 per share, with a total value of $18,980.00. Following the completion of the transaction, the insider now directly owns 5,161 shares of the company's stock, valued at $195,911.56. Learn More on Eric Fink's trading history.
Who are Global Blood Therapeutics' active insiders?: Global Blood Therapeutics' insider roster includes Eric Fink (Insider), Scott Morrison (Director), and Philip Pizzo (Director). Learn More on Global Blood Therapeutics' active insiders.

Eric Fink Insider Trading History at Global Blood Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/10/2021	Buy	500	$37.96	$18,980.00	5,161
10/5/2020	Sell	4,532	$60.00	$271,920.00
8/5/2020	Sell	2,454	$69.62	$170,847.48	950

Eric Fink Buying and Selling Activity at Global Blood Therapeutics

Global Blood Therapeutics Company Overview

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Today's Range

Now: $68.49

$68.49

50 Day Range

MA: $68.47

$68.07

$68.49

2 Week Range

Now: $68.49

$21.65

$73.02

Volume

74 shs

Average Volume

2,065,836 shs

Market Capitalization

$4.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45